{"id":"pertuzumab-zrc-3277","safety":{"commonSideEffects":[{"rate":"60–70","effect":"Diarrhea"},{"rate":"40–50","effect":"Nausea"},{"rate":"30–40","effect":"Fatigue"},{"rate":"30–40","effect":"Vomiting"},{"rate":"20–30","effect":"Rash"},{"rate":"5–10","effect":"Left ventricular dysfunction"},{"rate":"5–15","effect":"Febrile neutropenia"}]},"_chembl":{"chemblId":"CHEMBL2007641","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pertuzumab targets the extracellular domain II of HER2, a different epitope than trastuzumab, and prevents HER2 from forming heterodimers with HER3 and other HER family members. This dual mechanism—blocking both HER2 signaling directly and preventing ligand-induced dimerization—provides complementary inhibition of HER2-driven proliferation in cancer cells. It is often used in combination with trastuzumab and chemotherapy for enhanced efficacy.","oneSentence":"Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:38.871Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)"},{"name":"HER2-positive gastric or gastroesophageal junction cancer"}]},"trialDetails":[{"nctId":"NCT05283837","phase":"PHASE3","title":"A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)","status":"COMPLETED","sponsor":"Zydus Lifesciences Limited","startDate":"2022-09-26","conditions":"Metastatic Breast Cancer","enrollment":268}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pertuzumab (ZRC-3277)","genericName":"Pertuzumab (ZRC-3277)","companyName":"Zydus Lifesciences Limited","companyId":"zydus-lifesciences-limited","modality":"Biologic","firstApprovalDate":"","aiSummary":"Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling. Used for HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy), HER2-positive gastric or gastroesophageal junction cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}